Linax 5mg 10pcs

COMPOSITION
Linax Tablet : Each film coated tablet contains Linagliptin INN 5 mg .
DESCRIPTION
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP1)
and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active
incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of
glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose
homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after
meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta-cells in the presence of
normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic
alpha-cells, resulting in a reduction in hepatic glucose output.
INDICATION
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DOSAGE AND ADMINISTRATION
The recommended dose of Linagliptin is 5 mg once daily. Linagliptin tablets can be taken with or without food.
Renal or hepatic impairment: No dose adjustment required.
CONTRAINDICATION
Linagliptin is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria,
angioedema, or bronchial hyperreactivity.
PRECAUTION
When used with an Insulin secretagogue (e.g., sulfonylurea) or Insulin, consider lowering the dose of the Insulin
secretagogue or Insulin to reduce the risk of hypoglycemia.
If pancreatitis is suspected, Linagliptin should be discontinued.
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with
Linagliptin or any other antidiabetic drug.
SIDE EFFECT
Some of the less common side effects are nasopharyngitis, hypoglycemia.
USE IN PREGNANCY AND LACTATION
Pregnancy: There are no adequate and well-controlled studies in pregnant women. Linagliptin tablets should be
used during pregnancy only if the potential benefit of mother justifies the potential risk of the fetus.
Nursing mothers: Caution should be exercised when Linagliptin is administered to a nursing woman.
Pediatric patients: Safety and effectiveness of Linagliptin in patients below the age of 18 have not been
established.
USE IN GERIATRIC PATIENT
No adjustment of dosage is required in the elderly.
STORAGE
Linax should be stored between 15°C to 30° C.
PRESENTATION:
Linax Tablet: Each box contains 30 tablets in blister pack.